|
|
Article: CancerVax Resuming Phase III Trials Of Canvaxin In Melanoma.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
CancerVax Corp. is springing back into action as it resumes enrollment in Phase III melanoma studies of its lead product, Canvaxin.
The international trials, designed to study the therapeutic cancer vaccine in patients with Stage III or IV melanoma, were halted nearly a year ago by the company after the FDA raised questions related to Canvaxin's production. At the time the Carlsbad, Calif.-based company said it would work to develop manufacturing-related information, all the while stressing that the hold did not result from any clinical practice or safety concerns.
According to CancerVax, its submission of supplementary information ...